A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia.
A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia.
复制标题
DOI：
10.1038/sj.bjc.6603608
复制
发表时间：
2007-03-12
影响因子：
8.8
通讯作者：
Seckl, M. J.
中科院分区：
文献类型：
--
作者：
Powles, T.;Savage, P. M.;Stebbing, J.;Short, D.;Young, A.;Bower, M.;Pappin, C.;Schmid, P.;Seckl, M. J.
大多数因妊娠滋养细胞疾病(GTN)而需要化疗的妇女通过最初的化疗治愈。然而，一小部分人要么对治疗无效，要么在治疗完成后复发。这项研究调查了这些患者的特征和结局。患者是从查令十字医院GTD数据库中确定的。将这些复发疾病患者和难治性疾病患者的结果进行比较。1980至2004年间，1708名患者接受了GTN的化疗。60例(3.5%)患者在完成初始治疗后复发。复发的GTN患者总的5年生存率为93%(95%可信区间为86~100%)。低风险和高风险疾病患者的总存活率分别为100%(n=35)和84%(n=25)(95%CI：66-96%：P<；0.05)。11名患者未能进入缓解期并患有难治性疾病。与复发患者相比，这些患者的预后更差(5年生存率为43%(95%可信区间：12-73%P<；0.01))。复发的GTN患者预后良好。然而，患有原发化疗难治性疾病的患者表现不佳，这类患者需要新的治疗方法。
The majority of women requiring chemotherapy for gestational trophoblastic disease (GTN) are cured with their initial chemotherapy treatment. However, a small percentage either become refractory to treatment, or relapse after the completion of treatment. This study investigates the characteristics and outcome of these patients. Patients were identified from the Charing Cross Hospital GTD database. The outcome of these patients with relapsed disease was compared to those with refractory disease. Between 1980 and 2004, 1708 patients were treated with chemotherapy for GTN. Sixty (3.5%) patents relapsed following completion of initial therapy. The overall 5-year survival for patients with relapsed GTN was 93% (95% CI 86–100%). The overall survival for patients with low-risk and high-risk disease at presentation, who subsequently relapsed was 100% (n=35), and 84% (n=25) (95% CI: 66–96%: P<0.05), respectively. Eleven patients were identified who failed to enter remission and had refractory disease. These patients had a worse outcome compared to patients with relapsed disease (5-year survival 43% (95% CI:12–73% P<0.01)). The outcome of patients with relapsed GTN is good. However, patients with primary chemo-refractory disease do poorly and novel therapies are required for this group of patients.
登录
查看更多内容
DOI：
10.1016/s1521-6934(03)00091-9
发表时间：
2003-12-01
影响因子：
5.5
作者：
Soper, JT
通讯作者：
Soper, JT
影响因子：
4.7
作者：
Matsui, H;Suzuka, K;Sekiya, S
通讯作者：
Sekiya, S
影响因子：
45.3
作者：
Bower, M;Newlands, ES;Bagshawe, KD
通讯作者：
Bagshawe, KD
影响因子：
45.3
作者：
McNeish, IA;Strickland, S;Newlands, ES
通讯作者：
Newlands, ES
影响因子：
45.3
作者：
Newlands, ES;Mulholland, PJ;Rustin, GJS
通讯作者：
Rustin, GJS